Quantifies CYP7A1 using a double-antibody sandwich ELISA.
Brand
P450-Metric™
Development Stage
ADME
ADME Research Domain
Metabolism
Description
This advanced double-antibody sandwich ELISA kit is strictly designed for the reliable quantitative detection of Cytochrome P450 7A1 across diverse biological matrices. Featuring superior analytical sensitivity and minimal cross-reactivity, this research-use-only assay empowers scientists to meticulously investigate hepatic cholesterol homeostasis and bile acid synthesis. It serves as an essential analytical platform for evaluating lipid-modulating therapeutics and related pharmacokinetic profiles during preclinical ADME studies.
Features
Utilizing a double-antibody sandwich method, this assay delivers highly specific quantification of CYP7A1 to support advanced research in cholesterol homeostasis and hepatic drug clearance mechanisms.
Process Relevance
Monitoring CYP7A1 expression to assess cholesterol homeostasis and optimize lipid-lowering compound metabolism.
Application Stage
Preclinical drug discovery, ADME profiling, and pharmacokinetic research
Applications
Employ this reliable sandwich ELISA to accurately measure target enzyme concentrations in tissue homogenates and biological fluids.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Sample Type
Serum, plasma, tissue homogenates, cell lysates
Research Areas
ADME; Lipid Metabolism; Drug Metabolism; Pharmacokinetics
Upon receipt, please follow the storage recommendations in the USER MANUAL to maintain reagent stability. Follow recommended handling procedures to ensure consistent assay performance.
Storage Comment
Avoid repeated freeze-thaw cycles. Do not store at elevated temperatures for extended periods.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
As the rate-limiting enzyme in bile acid synthesis, Cytochrome P450 7A1 is central to hepatic cholesterol homeostasis. Its modulation by novel therapeutics is a key focus in ADME profiling to assess the clearance of lipid-lowering agents and potential xenobiotic disruptions to metabolic networks.